AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial

AstraZeneca and Amgen's TEZSPIRE (tezepelumab) met co-primary endpoints in the Phase III CROSSING trial for eosinophilic esophagitis (EoE), achieving statistically significant histologic remission and symptom improvements at week 24, sustained through week 52. At week 24, 64.8% of patients on the 210mg dose and 68.9% on the 420mg dose achieved histologic remission compared to 3.5% on placebo. Additionally, TEZSPIRE reduced dysphagia symptoms significantly, with improvements of 18.8 points and 22.0 points for the respective doses, compared to 14.7 points on placebo. The trial results were presented at the United European Gastroenterology Week 2026 in Barcelona.